摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Hydroxy-N-(8-methyl-2-oxo-7-(piperidin-4-yloxy)-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide | 1239437-99-0

中文名称
——
中文别名
——
英文名称
4-Hydroxy-N-(8-methyl-2-oxo-7-(piperidin-4-yloxy)-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide
英文别名
4-hydroxy-3-(3-methylbut-2-enyl)-N-(8-methyl-2-oxo-7-piperidin-4-yloxychromen-3-yl)benzamide
4-Hydroxy-N-(8-methyl-2-oxo-7-(piperidin-4-yloxy)-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide化学式
CAS
1239437-99-0
化学式
C27H30N2O5
mdl
——
分子量
462.546
InChiKey
IZUJYNUVFZWURQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    34
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    96.9
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    申请人:Calvet James P.
    公开号:US20110082098A1
    公开(公告)日:2011-04-07
    Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
    新比奴霉素类似物在治疗、抑制和/或预防自体显性多囊肾病(ADPKD)中的囊肿形成方法中是有用的。本公开提供了治疗ADPKD的方法,包括给予香豆素-3-羧酰胺新比奴霉素类似物的治疗有效量。因此,该方法可以包括给予新比奴霉素类似物的治疗有效量,以降低mTOR途径磷酸化蛋白P-mTOR、P-Akt和P-S6K的水平,或其组合。此外,该方法可以包括给予新比奴霉素类似物的治疗有效量,以降低Hsp-90客体蛋白CFTR、ErbB2、c-Raf和Cdk4的水平,或其组合。
  • NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES
    申请人:Blagg Brian S. J.
    公开号:US20120252745A1
    公开(公告)日:2012-10-04
    The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.
    本公开提供了具有替代noviose的诺维菌素类似物,其在癌症治疗中作为Hsp90抑制剂是有用的。
  • US9120774B2
    申请人:——
    公开号:US9120774B2
    公开(公告)日:2015-09-01
  • [EN] NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES<br/>[FR] ANALOGUES DE NOVOBIOCINE COMPORTANT DES GROUPES FONCTIONNELS GLUCIDIQUES MODIFIÉS
    申请人:UNIV KANSAS
    公开号:WO2010096650A1
    公开(公告)日:2010-08-26
    The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.
  • [EN] NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE<br/>[FR] ANALOGUES DE NOVOBIOCINE ET TRAITEMENT D'UNE MALADIE POLYKYSTIQUE DES REINS
    申请人:UNIV KANSAS
    公开号:WO2011041593A1
    公开(公告)日:2011-04-07
    Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
查看更多